Kyverna Therapeutics Inc. (NASDAQ: KYTX) announced details of its registrational Phase 3 trial design for KYV-101, a CAR T-cell therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE